MX2023007680A - Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina. - Google Patents

Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.

Info

Publication number
MX2023007680A
MX2023007680A MX2023007680A MX2023007680A MX2023007680A MX 2023007680 A MX2023007680 A MX 2023007680A MX 2023007680 A MX2023007680 A MX 2023007680A MX 2023007680 A MX2023007680 A MX 2023007680A MX 2023007680 A MX2023007680 A MX 2023007680A
Authority
MX
Mexico
Prior art keywords
methods
gemcitabine
treatment
maintenance therapy
bladder cancer
Prior art date
Application number
MX2023007680A
Other languages
English (en)
Inventor
Christopher Cutie
Dennis Giesing
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of MX2023007680A publication Critical patent/MX2023007680A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

Se proporcionan métodos para tratar carcinomas uroteliales del tracto inferior que comprenden administrar gemcitabina continuamente y localmente a la vejiga de un individuo en una terapia de inducción y/o terapia de mantenimiento.
MX2023007680A 2017-11-08 2020-07-13 Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina. MX2023007680A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762583394P 2017-11-08 2017-11-08

Publications (1)

Publication Number Publication Date
MX2023007680A true MX2023007680A (es) 2023-07-07

Family

ID=66439297

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004771A MX2020004771A (es) 2017-11-08 2018-11-07 Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.
MX2023007680A MX2023007680A (es) 2017-11-08 2020-07-13 Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020004771A MX2020004771A (es) 2017-11-08 2018-11-07 Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.

Country Status (18)

Country Link
US (3) US10792297B2 (es)
EP (1) EP3706763A4 (es)
JP (2) JP2021502347A (es)
KR (2) KR20200085822A (es)
CN (1) CN111787926A (es)
AU (1) AU2018366106A1 (es)
BR (1) BR112020008700A2 (es)
CA (1) CA3081839A1 (es)
DO (1) DOP2023000155A (es)
EA (1) EA202091143A1 (es)
IL (2) IL302714A (es)
JO (1) JOP20200124A1 (es)
MA (1) MA50581A (es)
MX (2) MX2020004771A (es)
PE (1) PE20210041A1 (es)
PH (1) PH12020550587A1 (es)
SG (1) SG11202003950WA (es)
WO (1) WO2019094517A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018306299B2 (en) 2017-07-25 2024-08-08 Taris Biomedical Llc Methods of treating tumor metastasis
KR20200085822A (ko) 2017-11-08 2020-07-15 타리스 바이오메디컬 엘엘씨 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법
WO2024092159A1 (en) * 2022-10-28 2024-05-02 Taris Biomedical Llc Methods of treating bladder cancer with gemcitabine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111203A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US6171298B1 (en) 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
WO2004026281A2 (en) 2002-09-23 2004-04-01 Microchips, Inc. Micro-reservoir osmotic release systems and microtube array device
CA2503193A1 (en) 2002-10-22 2004-05-06 The Biomerix Corporation Method and system for intravesicular delivery of therapeutic agents
US8361490B2 (en) 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
ES2400091T3 (es) 2005-08-11 2013-04-05 Massachusetts Institute Of Technology Dispositivo de suministro de fármacos intravesical y método
CA2650520A1 (en) 2006-04-24 2008-01-31 Gloucester Pharmaceuticals Treatment of ras-expressing tumors
EP1913962A1 (en) 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
ES2481454T3 (es) 2007-12-11 2014-07-30 Massachusetts Institute Of Technology Dispositivo implantable de administración de fármacos
MX2010010635A (es) 2008-04-04 2010-12-17 Lipella Pharmaceuticals Inc Tratamiento de la disfuncion de la vejiga usando toxina botulinum liposomal.
CN102159257B (zh) 2008-07-17 2015-11-25 米歇尔技术公司 药物递送医疗设备
KR101689786B1 (ko) 2008-08-09 2016-12-26 메사츄세츠 인스티튜트 어브 테크놀로지 남성 비뇨생식기 및 주위 조직을 치료하는 방법 및 체내이식형 약물 전달 장치
WO2010151893A1 (en) 2009-06-26 2010-12-29 Taris Biomedical, Inc. Implantable drug delivery devices and methods of making the same
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
AU2010339821B2 (en) 2009-12-17 2015-02-19 Taris Biomedical Llc Implantable device with intravesical tolerability and methods of treatment
WO2011089604A2 (en) 2010-01-20 2011-07-28 Theracoat Ltd Material and method for treating internal cavities
US20110218488A1 (en) 2010-03-05 2011-09-08 Taris Biomedical, Inc. Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites
BR112012030699A2 (pt) 2010-06-02 2016-09-13 Abraxis Bioscience Llc métodos para tratar câncer de bexiga
US9492266B2 (en) 2010-08-05 2016-11-15 Taris Biomedical Llc Ureteral stent drug delivery device, kit, and method
JP5945544B2 (ja) 2010-10-06 2016-07-05 タリス バイオメディカル エルエルシー 時間選択的に生体吸収可能または崩壊可能な薬剤送達システムおよび方法
US9457176B2 (en) 2010-10-06 2016-10-04 Taris Biomedical Llc Implantable drug delivery device with bladder retention feature
CN103347509B (zh) 2010-10-27 2016-06-08 普罗米蒂克生物科学公司 用于治疗癌症的化合物和组合物
WO2012079083A2 (en) 2010-12-10 2012-06-14 The Board Of Regents Of The University Of Nebraska Hemodialysis catheter with displaceable tubes to disrupt a fibrous sheath
US8979797B2 (en) 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
JP2014503554A (ja) 2011-01-10 2014-02-13 タリス バイオメディカル，インコーポレイテッド 膀胱痛及び刺激性排尿の持続的治療の使用のためのリドカインレジメン
ES2637388T3 (es) 2011-02-04 2017-10-13 Taris Biomedical, Inc. Dispositivo implantable para la liberación controlada de un fármaco de baja solubilidad
US20150005595A1 (en) 2011-12-30 2015-01-01 Kibur Medical, Inc. Implantable devices and methods for evaluation of active agents
JP6639228B2 (ja) 2012-03-29 2020-02-05 アルター・バイオサイエンス・コーポレーション 新生物を治療するための方法
US10058688B2 (en) 2012-05-09 2018-08-28 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
SI2890384T1 (sl) 2012-08-31 2022-02-28 Taris Biomedical Llc Sistemi za dostavo zdravila in postopki za zdravljenje raka sečnega mehurja, ki obsegajo oksaliplatin
WO2014036556A2 (en) 2012-08-31 2014-03-06 Taris Biomedical, Inc. Drug delivery systems and methods for treatment of prostate
WO2014138214A1 (en) 2013-03-05 2014-09-12 Taris Biomedical, Inc. Drug delivery devices and methods for controlled drug release through device orifice
KR102293280B1 (ko) 2013-03-15 2021-08-23 타리스 바이오메디컬 엘엘씨 약물-투과성 구성요소를 가지는 약물 전달 장치 및 방법
RU2669407C2 (ru) 2013-03-15 2018-10-11 ТАРИС Биомедикал ЛЛК Устройства для доставки лекарственных средств и способы доставки лекарственных средств
JP6431528B2 (ja) 2013-04-10 2018-11-28 マサチューセッツ インスチテュート オブ テクノロジーＭａｓｓａｃｈｕｓｅｔｔｓ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｔｅｃｈｎｏｌｏｇｙ 癌治療のための薬物局所送達装置及び方法
DE102013103986A1 (de) 2013-04-19 2014-10-23 B. Braun Avitum Ag Rezirkulationsvorrichtung eines extrakorporalen Blutbehandlungsgeräts
IL299897B2 (en) 2013-08-19 2024-02-01 Taris Biomedical Llc Devices and methods for administering multiple units of drug
US9215250B2 (en) 2013-08-20 2015-12-15 Janus Technologies, Inc. System and method for remotely managing security and configuration of compute devices
CN105792880A (zh) 2013-11-05 2016-07-20 塔里斯生物医药公司 渗透药物递送装置、套件以及方法
PT3113782T (pt) * 2014-03-06 2023-01-05 Taris Biomedical Llc Sistemas e métodos de administração de fármaco para tratamento do cancro da bexiga com gemcitabina
RU2591946C2 (ru) 2014-06-24 2016-07-20 Владимир Эдуардович Анников Способ изготовления гелеобразного водосодержащего взрывчатого состава
US10737078B2 (en) 2014-06-26 2020-08-11 Taris Biomedical Llc Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
JP7425534B2 (ja) 2015-04-23 2024-01-31 タリス バイオメディカル エルエルシー 薬物透過性構成要素を有する薬物送達デバイス及び方法
CN109475571A (zh) 2016-05-06 2019-03-15 塔里斯生物医药公司 治疗下尿路尿道上皮癌的方法
AU2018306299B2 (en) 2017-07-25 2024-08-08 Taris Biomedical Llc Methods of treating tumor metastasis
KR20200085822A (ko) 2017-11-08 2020-07-15 타리스 바이오메디컬 엘엘씨 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법
EP3829582A4 (en) 2018-08-01 2022-04-27 TARIS Biomedical LLC METHOD OF TREATMENT OF OVERACTIVE BLADDER USING TROSPIUM

Also Published As

Publication number Publication date
DOP2023000155A (es) 2023-12-29
JP2024009888A (ja) 2024-01-23
BR112020008700A2 (pt) 2020-10-27
KR20200085822A (ko) 2020-07-15
EP3706763A1 (en) 2020-09-16
US20190175637A1 (en) 2019-06-13
IL274343B2 (en) 2023-10-01
US20230321129A1 (en) 2023-10-12
IL302714A (en) 2023-07-01
KR20240119176A (ko) 2024-08-06
IL274343A (en) 2020-06-30
EA202091143A1 (ru) 2020-07-30
MA50581A (fr) 2020-09-16
JOP20200124A1 (ar) 2020-05-20
US20210085705A1 (en) 2021-03-25
MX2020004771A (es) 2020-10-19
JP2021502347A (ja) 2021-01-28
CA3081839A1 (en) 2019-05-16
US12029749B2 (en) 2024-07-09
PE20210041A1 (es) 2021-01-08
AU2018366106A1 (en) 2020-05-14
EP3706763A4 (en) 2021-08-11
CN111787926A (zh) 2020-10-16
IL274343B1 (en) 2023-06-01
SG11202003950WA (en) 2020-05-28
PH12020550587A1 (en) 2021-04-26
US10792297B2 (en) 2020-10-06
WO2019094517A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
IL261008A (en) Combined immunotherapy and cytokine control therapy for cancer treatment
WO2016025635A3 (en) Combination therapy for treating cancer
MX364705B (es) Sistemas y metodos para tratar el cancer y/o aumentar la funcion de organos.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2023007680A (es) Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.
MX2019011148A (es) Metodos de tratamiento.
MX2023006304A (es) Administracion de celulas t dise?adas para tratamiento de canceres en el sistema nervioso central.
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2018001755A (es) Vacuna contra viruela para tratamiento del cancer.
WO2016043874A3 (en) Combination therapy for treating cancer
MX2016014007A (es) Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab.
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
MX2017015896A (es) Agente anticancerigeno.
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
EP4353320A3 (en) Blood plasma and plasma fractions as therapy for tumor growth and progression
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
IL275517A (en) Combined methods and treatment of cancer
IL279591A (en) Cancer treatment methods using combination therapy
MX2019003751A (es) Proteina terapeutica.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
IL275913A (en) Methods and combined treatment for cancer treatment
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.